The study is testing a new study medicine (called NNC0705-0001), as a potential medicine to treat chronic systemic inflammation, which is known for increasing the risk of developing cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in our body, and what our body does to the study medicine. The participant will either get NNC0705-0001 or placebo (a "dummy medicine" without the active ingredient). Which treatment the participant gets is decided by chance. The study consists of 3 parts: PART A - single ascending dose (SAD); PART B - multiple ascending doses (MAD) and PART C - food effect (FE) on the pharmacokinetic (PK) properties of NNC0705-0001 and will last about 35 days (PART A) and 41 days (PART B and C).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
PART A: Number of treatment emergent adverse events (TEAE)
Timeframe: From time of dosing (day 1) to end of study (day 7)
PART B: Number of TEAEs
Timeframe: From time of dosing (day 1) to end of study (day 13)
AUC, SD; the area under the NNC0705-0001 plasma concentration-time curve after a single dose
Timeframe: From pre-dose (day 1 or day 8) to day 2 or day 9